Shattuck Labs Inc (STTK) - Total Assets
Based on the latest financial reports, Shattuck Labs Inc (STTK) holds total assets worth $100.33 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Shattuck Labs Inc shareholders equity for net asset value and shareholders' equity analysis.
Shattuck Labs Inc - Total Assets Trend (2018–2024)
This chart illustrates how Shattuck Labs Inc's total assets have evolved over time, based on quarterly financial data.
Shattuck Labs Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Shattuck Labs Inc's total assets of $100.33 Million consist of 87.0% current assets and 13.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 63.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Shattuck Labs Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Shattuck Labs Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shattuck Labs Inc's current assets represent 87.0% of total assets in 2024, a decrease from 96.3% in 2018.
- Cash Position: Cash and equivalents constituted 63.0% of total assets in 2024, up from 46.4% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Shattuck Labs Inc Competitors by Total Assets
Key competitors of Shattuck Labs Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Shattuck Labs Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.00 | 7.96 | 20.53 |
| Quick Ratio | 17.00 | 7.96 | 20.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $85.39 Million | $86.34 Million | $328.81 Million |
Shattuck Labs Inc - Advanced Valuation Insights
This section examines the relationship between Shattuck Labs Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.62 |
| Latest Market Cap to Assets Ratio | 2.68 |
| Asset Growth Rate (YoY) | -42.9% |
| Total Assets | $91.05 Million |
| Market Capitalization | $244.26 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Shattuck Labs Inc's assets at a significant premium (2.68x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Shattuck Labs Inc's assets decreased by 42.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shattuck Labs Inc (2018–2024)
The table below shows the annual total assets of Shattuck Labs Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $91.05 Million | -42.94% |
| 2023-12-31 | $159.56 Million | -22.29% |
| 2022-12-31 | $205.32 Million | -31.23% |
| 2021-12-31 | $298.58 Million | -14.44% |
| 2020-12-31 | $348.99 Million | +676.06% |
| 2019-12-31 | $44.97 Million | -34.03% |
| 2018-12-31 | $68.16 Million | -- |
About Shattuck Labs Inc
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inf… Read more